Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TriVascular2: A New Beginning

This article was originally published in Start Up

Executive Summary

Boston Scientific agreed to divest itself of its TriVascular abdominal aortic aneurysm company, selling it for $65 million to MPM Capital, New Enterprise Associates, Kearny Venture Partners and Delphi Ventures.

Related Content

The A-List: 2010's Trend-Shaping Series A Financings
TriVascular's Sequel Could Be a Blockbuster
The A-List: 2008's Trend Shaping Series A Financings
Market & Industry Briefs
Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q1 2008
In Search of the Perfect Aortic Endograft
In Search of the Perfect Aortic Endograft
Boston Scientific Shuffles and Sells in Bid to Right Ship
How To Fix A Guidant: Boston Scientific's Tobin Opens Playbook
Filling in the Gaps in AAA Repair

Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts